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Introduction: Systemic sclerosis (SSc) is a connective tissue disease of autoimmune nature
characterized by the triad of vascular injury, autoimmunity (cellular and humoral) and tis-
sue  ﬁbrosis. Autoantibodies do not seem to be simply epiphenomena, but are involved
in  disease pathogenesis. It is believed that the SSc-speciﬁc autoantibodies are responsi-
ble  both for amplifying immune response and targeting cell types that are relevant in the
pathophysiology of SSc.
Objectives: To correlate the proﬁle of the following speciﬁc autoantibodies: anti-centromere
(ACA), anti-topoisomerase I (topo I) and anti-RNA polymerase III (RNAP III) with clinical and
laboratory manifestations were observed in 46 patients with SSc in the Midwest region of
Brazil.
Methods: The occurrence of speciﬁc autoantibodies in 46 patients with SSc was investigated,
correlating the type of autoantibody with clinical and laboratory manifestations found.
Results: Among all patients evaluated, we found a predominance of females (97.8%), mean
age  50.21 years old, Caucasian (50%), limited cutaneous SSc (47.8%), time of diagnosis
between 5 and 10 years (50%), and disease duration of 9.38 years. According to the speciﬁc
autoantibody proﬁle, 24 patients were ACA-positive (52.2%), 15 were positive for anti-topo
I  (32.6%), and 7 showed positive anti-RNAP III (15.2%). The anti-topo I autoantibody cor-
related with diffuse scleroderma, with greater disease severity and activity, with worse
quality of life measured by the SHAQ index, with a higher prevalence of objective Ray-
naud’s phenomenon and digital pitting scars of ﬁngertips. The ACA correlated with limited
scleroderma, with earlier onset of disease, as well as higher prevalence of telangiectasias.
The  anti-RNAP III correlated with diffuse scleroderma, with a higher occurrence of subjec-tive  Raynaud’s phenomenon and muscle atrophy. There was no association between the
positivity for anti-topo I, ACA and anti-RNAP III antibodies and other variables related to
laboratory abnormalities, as well as Rodnan skin score and skin, vascular, musculoskeletal,
gastrointestinal, cardiopulmonary and renal manifestations.
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Conclusions: The clinical subtype of the disease and some clinical manifestations in SSc may
correlate positively with the presence of speciﬁc autoantibodies.
© 2014 Elsevier Editora Ltda. All rights reserved.
Autoanticorpos  em  esclerose  sistêmica  e  sua  correlac¸ão  com  as
manifestac¸ões  clínicas  da  doenc¸a em  pacientes  do  Centro-Oeste  do  Brasil
Palavras-chave:
Autoanticorpos
Esclerose sistêmica
Antitopoisomerase I
Anticentrômero
Anti-RNA polimerase III
r  e  s  u  m  o
Introduc¸ão: a esclerose sistêmica (ES) é uma enfermidade do tecido conjuntivo de caráter
autoimune caracterizada pela tríade de injúria vascular, autoimunidade (celular e humoral)
e  ﬁbrose tecidual. Os autoanticorpos não parecem ser simplesmente epifenômenos, mas sim
estarem envolvidos na patogênese da doenc¸a. Acredita-se que os autoanticorpos especíﬁcos
da  ES são responsáveis tanto pela ampliﬁcac¸ão da resposta imune quanto por alvejar os tipos
celulares que são relevantes na ﬁsiopatologia da ES.
Objetivos: correlacionar o perﬁl de autoanticorpos especíﬁcos (anti-SCL70, ACA, anti-POL3)
com as manifestac¸ões clínicas e laboratoriais observadas em 46 pacientes com ES da região
Centro-Oeste do Brasil.
Métodos: pesquisou-se a ocorrência de autoanticorpos especíﬁcos em 46 pacientes com
diagnóstico de ES e correlacionou-se o tipo de autoanticorpo com as manifestac¸ões clínicas
e  laboratoriais encontradas.
Resultados: dentre todos os pacientes avaliados, encontrou-se predomínio feminino (97,8%),
idade média de 50,21 anos, cor branca (50%), forma limitada da doenc¸a (47,8%), tempo de
diagnóstico entre cinco e 10 anos (50%) e tempo de evoluc¸ão da doenc¸a de 9,38 anos. De
acordo com o autoanticorpo especíﬁco, 24 pacientes apresentavam ACA positivo (52,2%),
15  apresentavam positividade para anti-SCL70 (32,6%) e sete apresentavam anti-POL3 pos-
itivo (15,2%). O autoanticorpo anti-SCL70 se correlacionou com a forma difusa da doenc¸a,
com  maior gravidade e atividade da doenc¸a, com pior qualidade de vida medida pelo índice
HAQ, com maior prevalência de fenômeno de Raynaud objetivo e microcicatrizes de polpas
digitais. O ACA se correlacionou com a forma limitada da doenc¸a, com o início mais pre-
coce  da enfermidade, bem como com maior prevalência de telangiectasias nos pacientes.
Já  o anti-POL3 se correlacionou com a forma difusa da doenc¸a, com maior ocorrência
de  fenômeno de Raynaud subjetivo e de atroﬁa muscular. Para as demais variáveis rela-
cionadas às alterac¸ões laboratoriais, bem como em relac¸ão ao escore cutâneo de Rodnan e
às  manifestac¸ões cutâneas, vasculares, musculoesqueléticas, gastrintestinais, cardiopul-
monares e renais, não houve associac¸ão entre elas e a positividade para os anticorpos
anti-SCL70, ACA e anti-POL3.
Conclusões: a forma clínica da doenc¸a e algumas manifestac¸ões clínicas na ES podem se
correlacionar positivamente com a presenc¸a de autoanticorpos especíﬁcos.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Systemic sclerosis (SSc) is a connective tissue disease of
autoimmune nature, extremely heterogeneous in its clin-
ical presentation, with involvement of multiple systems,
and following a variable and unpredictable course.1 Its eti-
ology remains unknown, with a multifactorial cause being
suggested, possibly triggered by environmental factors in a
genetically predisposed individual.2
The hallmark of SSc is microvasculopathy, activation of
ﬁbroblasts and excessive collagen production.3 It is a unique
disease as it has features of three distinct pathophysiolo-
gical processes; it consists of the triad of vascular injury,
autoimmunity (cellular and humoral) and tissue ﬁbrosis,leading to involvement of skin, in addition to several inter-
nal organs such as lungs, heart, gastrointestinal tract, among
others.3,4
It is believed that the link between initial vascular involve-
ment and the ﬁnal consequence of the disease (tissue ﬁbrosis)
could be represented by autoimmunity. Circulating antibodies,
alteration of immune mediators and inﬁltration of mono-
nuclear cells in affected organs represent a positive argument
for the hypothesis that dysfunction of the immune system
leads to illness.5,6
It is described that highly speciﬁc antibodies can be
detected in the sera of virtually all patients with SSc.7 A
review article by Zimmermann and Pizzichini highlights that
speciﬁc antibodies represent one of the hallmarks of the
disease and constitute the most evident expression of the
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nvolvement of the humoral immune system in the genesis
f SSc.8 These autoantibodies have fundamental character-
stics of a response triggered by the antigen, being mainly
epresented by: centromere antibodies (ACA), anti-DNA topo-
somerase I (anti-topo I), and anti-RNA antibodies polymerase
II (anti-RNAP III).9–12
Recent studies highlight the pathogenic potential of
utoantibodies in SSc patients, suggesting that speciﬁc anti-
odies against ﬁbroblasts, endothelial cells and receptors for
latelet-derived growth factor (PDGF) can directly cause acti-
ation of ﬁbroblasts and endothelial cells and contribute to
issue damage.1,13,14
There is evidence to support the idea that the complexity of
he SSc seems to represent another collection of phenotypes
ompared to a single disease entity. Thus, these genetic asso-
iations may actually be related to distinct phenotypes in the
Sc based on a pattern of autoantibodies.15
The region of the HLA genes is a clear example
f genetic polymorphism in the development of SSc.15
LA association studies were very inconsistent when
atients were grouped by race or ethnicity.15,16 How-
ver, when patients with SSc were grouped according
o the autoantibody proﬁle, the ﬁndings were consistent
cross the different ethnic groups.15 For example, HLA-
RB1*01–DQB1*0501 are more  common in patients with
CA-positive SSc while haplotypes HLA-DRB1*11–DQB1*0301
ave been associated with the positivity of anti-topo I
ntibodies.16
The mechanisms postulated for the development of
utoantibodies in SSc patients include: molecular mimicry,
hronic hyper-reactivity of B lymphocytes from intrinsic
bnormalities of the cell and increased expression, or
ltered subcellular localization of potentially auto-antigenic
eptides.1 Some antibodies do not appear to be simply
piphenomena, but to be involved in disease pathogenesis,17
ossibly by amplifying the immune response and targeting
ell types that are relevant in the pathophysiology of the
isease.18
The importance of the study of autoantibodies in SSc lies in
he fact that some of them have association with the disease
nd participate in the criteria proposed by LeRoy and Medsger
or early diagnosis of the condition, which gives them con-
iderable diagnostic value.9,10,19 Moreover, they are associated
ith certain phenotypic traits of the disease, and are used to
id in the classiﬁcation and characterization of two major dis-
ase subtypes: diffuse cutaneous SSc and limited cutaneous
Sc.10,20 Also, a close relationship between levels of anti-topo I
nd severity of skin involvement and global disease activity in
Sc was observed, revealing a possible prognostic role.10,21 In
ddition, signiﬁcant correlations between the pattern of anti-
ody proﬁle presented and the therapeutic response have been
eported.22
bjectiveso correlate the proﬁle of speciﬁc autoantibodies (ACA, anti-
opo I and anti-RNAP III) with clinical manifestations observed
n 46 patients with SSc followed in a university center from the
idwest region of Brazil.
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Methods
This is an observational study of cross-sectional design, with
prospective analysis of patient data.
A random selection of 46 patients was carried out from a
survey of the medical records of the Department of Rheuma-
tology of the University Hospital of the School of Medicine of
the Federal University of Mato Grosso do Sul (FMUFMS).
The patients were divided into three groups, according to
the positivity of one of the speciﬁc autoantibodies (ACA, anti-
topo I and anti-RNAP III).
Patients should meet the following inclusion criteria:
• Meet the 2013 new classiﬁcation Criteria for SSc;23
• In cases of absence of skin thickening, they should meet the
2001 LeRoy and Medsger’s criteria of early SSc;24
• They should have signed a Consent Form previously
approved by the Research Ethics Committee of UFMS.
• Patients who presented with other associated infectious
diseases or malignancies were excluded.
The socio-demographic and clinical information was
obtained from the patient medical records and complemented
with two interviews, within a time interval of 6 months. In
the ﬁrst appointment, demographic and clinical data were col-
lected, including disease duration, year of diagnosis, modiﬁed
Rodnan skin score,25 autoantibodies test, thorough clinical
examination and current treatment.
Disease duration was divided into two: total time in years
of Raynaud’s phenomenon (RP) before diagnosis of the disease
(RP time) and total time in years of clinical manifestations of
the disease after diagnosis, not considering RP (time without
RP).
Speciﬁc data about Medsger’s Severity Criteria26 and
Valentini’s Criteria of Activity27 were collected on speciﬁc for-
mularies at baseline assessment and after 6 months. The
Scleroderma Health Assessment Questionnaire (SHAQ)28 was
also collected in the initial patient assessment and on second
assessment.
SHAQ is a measure of function in SSc, being a helpful tool
for the assessment of physical functional disability29 and the
impact of the disease on patient’s physical and mental well-
being.30 The objective was to correlate if the rate of disability
measured by SHAQ would be higher in one of the three groups
of patients with speciﬁc autoantibodies (ACA, anti-topo I and
anti-RNAP III).
Sera properly frozen at −50 ◦C and stored at the Laboratory
of the University Hospital of UFMS from previously selected
patients was used for performing the research.
a) For the examination of anti-centromere (ACA) – we  used
the indirect immunoﬂuorescence technique and having
HEp2 cells as substrate according to the criteria of the
II Brazilian Consensus of antinuclear antibody in Hep-2
(2003) cells,31 for the interpretation of results.b) For the examination of anti-DNA topoisomerase 1 (anti-
topo I) – enzyme immunoassay technique was used,21
being non-reactive if <20 units, weakly positive between 20
and 39 units, moderately positive between 40 and 80 units
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Fig. 1 – Percentage of patients with positive antibody to
anti-topo I, ACA and anti-RNAP III among patients with
different clinical subtypes of the disease. Each column
represents the percent of patients. *Signiﬁcant difference
compared to patients with positive anti-topo I and
anti-RNAP III, in limited scleroderma. **Signiﬁcant
difference compared to patients with positive ACA, in
diffuse scleroderma (chi-square test; p < 0.050).232  r e v b r a s r e u m a t
and strongly positive if >80 units. A speciﬁc kit QUANTA
Lite TM Scl-70 was used from Laboratory INOVA (INOVA
Diagnostics, Inc., San Diego, CA, USA), following the man-
ufacturer’s speciﬁcations.
(c) Anti-RNA polymerase III (anti-RNAP III) antibody –
examinations were performed in duplicate using ELISA
technique, as previously described.32 Values <20 units
were considered negative, weakly positive if between 20
and 39 units, moderately positive if between 40 and 80
units and strongly positive if >80 units.
Statistical  analysis
Comparison of patients with positive anti-topo I antibody, ACA
or anti-RNAP III in relation to the quantitative variables eval-
uated in this study was performed by one-way ANOVA.
The chi-square test was used to assess the association
between the results for the antibodies (ACA, anti-topo I and
anti-RNAP III), with qualitative variables measured in this
study. The results of the other variables were presented in
the form of descriptive statistics or in the form of tables and
graphs. Statistical analysis was performed using SPSS soft-
ware, version 20.0, considering a signiﬁcance level of 5%.
Results
Of the 46 patients included, 45 were women (97.8%) and 1
was a man  (2.2%), with a mean age of 50.21 ± 3.55 years
(mean ± standard error).
The race of the patients was as follows: 23 patients were
classiﬁed as Caucasians (50.0%), 21 as mixed (45.7%) and 2
patients, black (4.3%).
Regarding the diagnosis, 42 diagnosed patients met  the
2013 ACR/EULAR classiﬁcation Criteria for SSc (91.3%). The
4 patients (8.7%) who did not meet these criteria met
LeRoy/Medsger’s criteria for early SSc.
Regarding the clinical subtypes of the disease, 22 patients
had limited cutaneous SSc (47.8%), 16 patients had the diffuse
cutaneous SSc (34.8%), 3 patients had the early form (6.5%),
5 patients had overlap form (10.9%) and none had the Sine
Scleroderma form. These results are shown in Fig. 1.
Regarding time since diagnosis, 12 patients were diagnosed
for more  than 10 years (26.1%), 23 patients were diagnosed
between 5 and 10 years (50.0%) and 11 patients were diagnosed
for less than 5 years (23.9%).
The time for disease progression of patients in general was
9.38 ± 3.08 years.
Among all patients, 24 showed positive ACA (52.2%), 15
were positive for anti-topo I (32.6%) and 7 were positive for
anti-RNAP III (15.2%).
Results regarding socio-demographic and clinical parame-
ters in patients with positive ACA, anti-topo I or anti-RNAP III,
are presented in Table 1.
There was no signiﬁcant difference between patients with
positive anti-topo I, ACA or anti-RNAP III antibodies in relation
to the quantitative variables age, duration of RP before diag-
nosis, and duration of illness without counting RP. Moreover,
SHAQ of patients with positive anti-topo I was signiﬁcantly
higher than that for patients with positive ACA or anti-RNAPIII antibody (p < 0.05). The same result was observed in relation
to the scale of activity. Moreover, SHAQ among patients with
positive ACA or anti-topo I was higher than that for patients
with positive anti-RNAP III antibody (p < 0.05).
For the scale of severity, the score among patients with pos-
itive anti-topo I antibody was higher than that for patients
with positive ACA antibody (p < 0.05), but with no difference
for patients with positive anti-RNAP III antibody (p > 0.05).
There was no further association between positive anti-topo
I, ACA or anti-RNAP III antibodies and nominal or ordinal
qualitative variables of gender, race, time since diagnosis and
2013 ACR/EULAR classiﬁcation criteria for SSc. However, there
was an association between positive anti-topo I, ACA or anti-
RNAP III antibodies and the clinical subtype of the disease
(p < 0.001), with the percentage of patients with limited dis-
ease among patients with positive ACA antibody (83, 3%, n = 20)
being signiﬁcantly higher than that among patients with pos-
itive anti-topo I and anti-RNAP III antibody (0.0%, n = 0 and
28.6%, n = 2, respectively). On the other hand, the percentage
of patients with diffuse disease, among patients with pos-
itive anti-topo I and anti-RNAP III (86.7%, n = 13 and 42.9%,
n = 3), respectively, was signiﬁcantly higher than that among
patients with positive ACA (0.0%, n = 0) antibody.
Table 2 shows the results for the skin, vascular and mus-
culoskeletal manifestations in patients with a positive result
for anti-topo I, ACA and anti-RNAP III antibodies. In this eval-
uation, it was observed that the percentage of patients with
positive anti-topo I antibody, which had objective RP (93.3%,
n = 14) was signiﬁcantly higher than that of patients with pos-
itive anti-RNAP III antibody, which also showed objective RP
(42.9%, n = 3, p < 0.05). On the other hand, the percentage of
patients with positive anti-RNAP III antibody, who  had sub-
jective RP (57.1%, n = 4), was signiﬁcantly higher than that of
r e v b r a s r e u m a t o l . 2 0 1 5;5 5(3):229–239 233
Table 1 – Demographic and clinical features of patients with positive anti-topo I, ACA or anti-RNAP III antibodies.
Variable Positive antibody p-Value
Anti-topo I ACA Anti-RNAP III
Demographics
Age 46.27  ± 1.82 54.21 ± 2.72 50.14 ± 6.10 0.149
Sex
Male 6.7 (1) 0.0 (0) 0.0 (0) 0.348
Female 93.3 (14) 100.0 (24) 100.0 (7)
Race
Caucasian 33.3 (5) 54.2 (13) 71.4 (5) 0.516
Mixed 60.0 (9) 41.7 (10) 28.6 (2)
Black 6.7 (1) 4.2 (1) 0.0 (0)
Length of diagnosis
Less than 5 years 13.3 (2) 25.0 (6) 42.9 (3) 0.384
Between 5 and 10 years 53.3 (8) 45.8 (11) 57.1 (4)
More than 10 years 33.3 (5) 29.2 (7) 0.0 (0)
Time of RP before diagnosis 2.27 ± 0.68 5.87 ± 1.87 0.86 ± 0.34 0.136
Time of disease without counting RP 7.53 ± 1.19 9.17 ± 5.56 11.43 ± 2.51 0.296
ACR/EULAR criteria
Yes 100.0  (15) 83.3 (20) 100.0 (7) 0.134
No 0.0 (0) 16.7 (4) 0.0 (0)
Clinical subtype
Limited 0.0 (0)b 83.3 (20)a 28.6 (2)b <0.001
Diffuse 86.7 (13)a 0.0 (0)b 42.9 (3)a
Recent onset 0.0 (0)a 12.5 (3)a 0.0 (0)a
Overlap 13.3 (2)a 4.2 (1)a 28.6 (2)a
Sine scleroderma 0.0  (0)a 0.0 (0)a 0.0 (0)a
Outcome measurements
SHAQ 0.90 ± 0.11a 0.64 ± 0.08a 0.16 ± 0.06b <0.001
Severity Scale 6.47 ± 0.80a 4.25 ± 0.48b 4.43 ± 1.04ab 0.044
Activity scale 3.20 ± 0.35a 1.94 ± 0.21b 1.64 ± 0.37b 0.002
The results are presented as mean ± standard error of the mean or relative frequency (absolute frequency).
p-Value in one-way ANOVA or chi-square test.
Different letter on lines indicate signiﬁcant difference among antibodies.
ACA, anticentromere antibodies; anti-topo I, anti-DNA topoisomerase I antibodies; anti-RNAP III, anti RNA polymerase III antibodies; RP, Ray-
naud’s phenomenon; ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; SHAQ, Scleroderma Health
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atients with positive anti-topo I antibody, which also showed
ubjective RP (6.7%, n = 1).
Patients with positive anti-topo I antibody showed more
igital pitting scars of ﬁngertips than patients with positive
CA antibody (p < 0.05). Furthermore, patients with positive
CA antibody had more  telangiectasia than patients with
ositive anti-topo I antibody (p < 0.050). Furthermore, patients
ith positive anti-RNAP III antibody had more  muscle atro-
hy than patients with positive ACA antibody (p < 0.050). These
esults are presented in Fig. 2. For the other variables related to
kin, vascular and musculoskeletal manifestations, there was
o association between them and the positivity for anti-topo
, ACA and anti-RNAP III antibodies. There was also no sig-
iﬁcant difference between patients with positivity for these
hree antibodies in relation to skin score (p = 0.065).
The results related to gastrointestinal, cardiopulmonary
nd renal manifestations in patients with positive anti-topo
, ACA or anti-RNAP III are presented in Table 3. There was no
ssociation between the presence of autoantibodies speciﬁc
or SSc and the variables studied.The results of the laboratory tests (ESR, CRP, CPK, creat-
inine, C3 and C4), antibody tests (anti-Ro, anti-La, anti-Sm,
anti-RNP and anti Jo-1) and changes observed on hand radio-
graphs in patients with positive anti-topo I, ACA and/or
anti-RNAP III antibodies are shown in Table 4, where a lack
of statistical signiﬁcance for all the studied parameters can be
seen.
Discussion
In our study, a unique sample was deﬁned that was repre-
sentative of the Midwest region of Brazil, characterized by a
heterogeneous group of patients with various spectrums of
disease and different stages of clinical manifestations and
disease activity, but that is very similar to other patient popu-
lations in the country and even from other locations.33–38This study objective was to investigate the correlation
between the proﬁle of speciﬁc autoantibodies (ACA, anti-topo
I or anti-RNAP III) and clinical and laboratory manifesta-
tions in this population of patients with SSc. Similar to
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Table 2 – Distribution of patients according to the skin, vascular and musculoskeletal manifestations in patients with
positive anti-topo I, ACA or anti-RNAP III antibodies.
Variable Positive antibody p-Value
Anti-topo I ACA Anti-RNAP III
Skin manifestations
Calcinosis
Yes 20.0 (3) 25.0 (6) 14.3 (1) 0.817
No 80.0 (12) 75.0 (18) 85.7 (6)
Hands
No changes 13.3 (2) 20.8 (5) 28.6 (2) 0.685
With changes 86.7 (13) 79.2 (19) 71.4 (5)
Findings on hands (n = 37)
Edematous phase 15.4 (2) 36.8 (7) 20.0 (1) 0.735
Indurative phase 46.2 (6) 31.6 (6) 40.0 (2)
Atrophic phase 38.5 (5) 31.6 (6) 40.0 (2)
Skin score (Rodnan modiﬁed) 16.33 ± 2.03 10.79 ± 1.30 13.86 ± 2.80 0.065
Vascular manifestations
RP
Objective 93.3 (14)a 66.7 (16)ab 42.9 (3)b 0.036
Subjective 6.7 (1)b 33.3 (8)ab 57.1 (4)a
Absent 0.0 (0) 0.0 (0) 0.0 (0)
Digital pitting scars of ﬁngertips
Yes 53.3 (8)a 16.7 (4)b 14.3 (1)ab 0.031
No 46.7 (7)b 83.3 (20)a 85.7 (6)ab
Active ulcers
Yes 20.0 (3) 8.3 (2) 0.0 (0) 0.316
No 80.0 (12) 91.7 (22) 100.0 (7)
Necrosis or amputation
Yes 13.3 (2) 12.5 (3) 0.0 (0) 0.602
No 86.7 (13) 87.5 (21) 100.0 (7)
Telangiectasias
Yes 53.3 (8)b 87.5 (21)a 57.1 (4)ab 0.045
No 46.7 (7)a 12.5 (3)b 42.9 (3)ab
Musculoskeletal manifestations
Arthritis/synovitis
Yes 40.0 (6) 37.5 (9) 0.0 (0) 0.134
No 60.0 (9) 62.5 (15) 100.0 (7)
Flexion contracture
Yes 26.7 (4) 8.3 (2) 14.3 (1) 0.300
No 73.3 (11) 91.7 (22) 85.7 (6)
Tendon friction rubs
Yes 6.7 (1) 4.2 (1) 0.0 (0) 0.773
No 93.3 (14) 95.8 (23) 100.0 (7)
Muscle weakness
Yes 20.0 (3) 8.3 (2) 28.6 (2) 0.347
No 80.0 (12) 91.7 (22) 71.4 (5)
Atrophy
Yes 6.7 (1)ab 4.2 (1)b 42.9 (3)a 0.012
No 93.3 (14)ab 95.8 (23)a 57.1 (4)b
The results are presented as mean ± standard error of the mean or relative frequency (absolute frequency).
p-Value in one-way ANOVA or chi-square test.
Different letter on lines indicate signiﬁcant difference among antibodies.
ACA, anticentromere antibodies; anti-topo I, anti-DNA topoisomerase I antibodies; anti-RNAP III, anti RNA polymerase III antibodies; RP,
Raynaud’s phenomenon.
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Table 3 – Distribution of patients according to gastrointestinal, cardiopulmonary and renal manifestations in patients
with positive anti-SCL70, ACA or anti-POL3.
Variable Positive antibody p-Value
Anti-topo I ACA Anti-RNAP III
Gastrointestinal manifestations
Esophagus involvement
Yes 73.3 (11) 70.8 (17) 57.1 (4) 0.730
No 26.7 (4) 29.2 (7) 42.9 (3)
Other GI manifestations
GERD 26.7 (4) 16.7 (4) 0.0 (0) 0.304
Esophagitis 20.0 (3) 16.7 (4) 42.9 (3) 0.329
Gastritis 13.3 (2) 20.8  (5) 14.3  (1) 0.812
Esophagic hypotonia 20.0 (3) 25.0 (6) 0.0 (0) 0.340
Esophageal dilation 6.7 (1) 4.2 (1) 14.3 (1) 0.634
Cardiopulmonary manifestations
VFC 76.27 ± 3.27 86.50 ± 2.56 83.71 ± 4.47 0.054
VFC – classiﬁcation
>80% 40.0 (6) 70.8 (17) 42.9 (3) 0.282
Between 70 and 80% 40.0 (6) 20.8 (5) 57.1 (4)
Between 50 and 69% 13.3 (2) 8.3 (2) 0.0 (0)
<50% 6.7 (1) 0.0 (0) 0.0 (0)
Chest CT
Normal 26.7 (4) 62.5 (15) 42.9 (3) 0.089
Altered 73.3 (11) 37.5 (9) 57.1 (4)
Findings on CT (n = 24)
Fibrosis 72.7 (8) 66.7 (6) 75.0 (3) 0.938
“Ground-glass” pattern 27.3 (3) 33.3 (3) 25.0 (1)
Echo PSAP 32.50 ± 5.50 37.25 ± 3.64 32.67 ± 12.25 0.882
Echocardiogram (n = 26)
Normal 40.0 (6) 54.2 (13) 14.3 (1) 0.164
Altered 60.0 (9) 45.8 (11) 85.7 (6)
Findings on echocardiogram
Valvulopathy 33.3 (5) 25.0 (6) 28.6 (2) 0.854
Concentric LVH 20.0 (3) 12.5 (3) 28.6 (2) 0.583
LV diastolic dysfunction 6.7 (1) 16.7  (4) 28.6  (2) 0.395
Mild or moderate PAH 6.7  (1) 8.3  (2) 28.6 (2) 0.260
Pericarditis 13.3 (2) 12.5 (3) 0.0 (0) 0.602
Renal manifestations
Renal crisis
Yes 0.0 (0) 0.0 (0) 0.0 (0) –
No 100.0 (15) 100.0 (24) 100.0 (7)
The results are presented as mean ± standard error of the mean or relative frequency (absolute frequency).
p-Value in one-way ANOVA or chi-square test.
ACA, anticentromere antibodies; anti-topo I, anti-DNA topoisomerase I antibodies; anti-RNAP III, anti-RNA polymerase III antibodies; GI, gas-
trointestinal; GERD, gastroesophageal reﬂux disease; VFC, vital functional capacity; CT, computed tomography; Echo PSAP, pulmonary artery
cle hy
o
a
y
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sestimated pressure by transthoracic echocardiogram; LVH, left ventri
ther populations, our patients were mostly female (97.83%)
nd with limited scleroderma (47.8%), with a mean age of 50
ears and caucasian (50.0%). In 65% of the patients, RP was the
rst disease manifestation before diagnosis, time since diag-
osis occurred mainly between 5 and 10 years (50.0%), mean
isease duration of 9 years, and average modiﬁed Rodnan
kin score of 13.66. Regarding speciﬁc antibodies, 52.2% of the
atients had positive ACA, 32.6% were positive for anti-topo I
nd 15.2% were positive for anti-RNAP III.
In Brazil, recently two different groups of researchers in the
outhern region described the occurrence of major speciﬁcpertrophy; LV, left ventricle; PAH, pulmonary artery hypertension.
autoantibodies in patients with SSc and both authors high-
lighted the importance of autoantibodies in the evaluation of
patients with SSc.33,34
The ﬁrst group from Hospital Evangélico de Curitiba (HUEC)
found, in 66 SSc patients, the prevalence of ACA, anti-topo
I and anti-U1-RNP, respectively in 33.3%, 17.8% and 11.8%
of patients.33 Although the percentage of each autoantibody
found in our study is greater for ACA and anti-topo I, the order
of distribution among speciﬁc autoantibodies was identical.
The authors from HUEC also observed an association of anti-
topo I with diffuse scleroderma and digital pitting scars of
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Table 4 – Distribution of patients according to the laboratory tests in patients with anti-topo I, ACA or anti-RNAP III
positive.
Variable Positive antibody p-Value
Anti-topo I ACA Anti-RNAP III
ESR 37.00 ± 6.23 22.63 ± 3.58 22.86 ± 5.06 0.076
CRP 13.82 ± 6.56 9.53 ± 2.72 7.36 ± 2.29 0.664
CPK 136.00 ± 45.85 120.83 ± 13.48 107.43 ± 15.68 0.846
C3 122.33 ± 5.69 138.00 ± 6.49 124.29 ± 9.16 0.199
C4 28.73 ± 2.21 35.38 ± 2.25 36.14 ± 1.92 0.089
Anti-Ro
Positive 26.7 (4) 4.2 (1) 0.0 (0) 0.054
Negative 73.3 (11) 95.8 (23) 100.0 (7)
Anti-La
Positive 6.7 (1) 0.0 (0) 0.0 (0) 0.348
Negative 93.3 (14) 100.0 (24) 100.0 (7)
Anti-RNP
Positive 26.7 (4) 4.2 (1) 28.6 (2) 0.092
Negative 73.3 (11) 95.8 (23) 71.4 (5)
Anti-Jo 1
Positive 6.7 (1) 4.2 (1) 0.0 (0) 0.773
Negative 93.3 (14) 95.8 (23) 100.0 (7)
Hand X-ray
Normal 53.3 (8) 50.0 (12) 71.4 (5) 0.603
Altered 46.7 (7) 50.0 (12) 28.6 (2)
Findings on hand X-ray (n = 21)
Calcinosis 14.3 (1) 50.0 (6) 50.0 (1) 0.283
Reabsorption (proximal phalange) 85.7 (6) 50.0 (6) 50.0 (1)
The results are presented as mean ± standard error of the mean or relative frequency (absolute frequency).
p-Value in one-way ANOVA or chi-square test.
ACA, anticentromere antibodies; anti-topo I, anti-DNA topoisomerase I antibodies; anti-RNAP III, anti RNA polymerase III antibodies; ESR,
ne pherythrocyte sedimentation rate; CRP, C-reactive protein; CPK, creati
component.
ﬁngertips; however, they found an association between this
autoantibody and the presence of cardiomyopathy. Unlike our
study, ACA was protective for cardiomyopathies and anti-U1-
RNP was more  common in overlap forms.33
The second group from Hospital de Clínicas of the Fed-
eral University of the state of Paraná (HC-UFPR) investigated
the prevalence of anti-RNAP III, anti-topo I and ACA in 85
SSc patients and found their presence in 41.18%; 31.76% and
30.59% of patients, respectively.34 Although it was noted that
the limited form was the most prevalent among patients, this
study found very high prevalence of positive anti-RNAP III,
which is related to diffuse cutaneous SSc. Our study has val-
idated the same clinical features observed in the group of
patients from HC-UFPR who  were anti-topo I-positive, such as
association with diffuse scleroderma, the presence of active
disease and digital ulcers. However, the group from HC-UFPR
found an association between synovitis and positivity for anti-
RNAP III, and greater prevalence of systemic hypertension and
cardiac conduction block in patients with positive ACA.34
In the present work, ACA was mainly correlated with
limited cutaneous SSc, with earlier onset of disease, as well as
higher prevalence of telangiectasias. ACA was found in 52.2%
of patients and, in the literature, ACAs were observed in about
20–30% of patients with SSc10,12 and in 55–80% of patients with
the limited form9, although it can vary among different ethnicosphokinase; C3, C3 complement component; C4, C4 complement
populations.10,12 ACAs have predictive value for future devel-
opment of SSc in patients with RP and are associated with
limited cutaneous involvement, peripheral vascular damage
and calcinosis.10,12 However, no greater prevalence of calci-
nosis in our patients with the limited form was observed. The
presence of ACA generally provides a better prognosis than
that seen with other antibodies, since they are less frequently
associated with interstitial lung ﬁbrosis,10,12 as observed in our
study, although not achieving statistical signiﬁcance.
In this study, the anti-topo I autoantibody was mainly cor-
related with the diffuse cutaneous SSc, with greater disease
severity and activity, with worse quality of life as measured
by SHAQ index, a higher prevalence of objective RP, and
digital pitting scars of ﬁngertips. We found anti-topo I in
32.6% of patients, in accordance with the literature, which
describes this antibody in 40% of patients with SSc,12 in about
28–70% patients with the diffuse cutaneous SSc9,10,12 and in
less than 10% of patients with limited scleroderma.9–11 As
observed in our patients, it is described that ethnic differ-
ences signiﬁcantly affect the prevalence of anti-topo I, and
it is observed to a lesser extent in Caucasians. Anti-topo
I, when determined by immunodiffusion, is virtually never
seen in healthy individuals, in other diseases of the connec-
tive tissue, or in patients with primary RP.10,12 Its presence is
described as related to worse prognosis, global disease activity,
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Fig. 2 – Percentage of patients with clinical manifestations
such as digital pitting scars of ﬁngertips, telangiectasias
and muscle atrophy, among patients with positive
anti-topo I, ACA and anti-RNAP III. Each column represents
the percent of patients. *Signiﬁcant difference compared to
patients with positive ACA and anti-RNAP III. **Signiﬁcant
difference compared to patients with positive anti-topo I
and anti-RNAP III. ***Signiﬁcant difference compared to
patients with positive anti-topo I and ACA (chi-square test;
p < 0.050).
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ity and severity, and impairment in quality of life as measuredeverity of skin involvement, interstitial lung disease and
ardiac involvement.9,10,12,39–41 However, cardiopulmonary
anifestations were not more  prevalent or more  severe in this
tudy.
However, in this work, the anti-RNAP III was primarily cor-
elated with diffuse scleroderma, since other two patients
ith inﬂammatory myopathy-associated positive anti-RNAP
II had diffuse cutaneous involvement. Interestingly, both
atients with overlap were not positive for anti-Jo1 antibody.
oreover, we observed a higher frequency of subjective RP
nd muscle atrophy in our patients. We  found anti-RNAP III
n 15.2% of patients, but other published studies describes
 prevalence of this antibody at different frequencies, prob-
bly related to genetic and racial differences. Its prevalence
anged from 4 to 9.4% in French, 12% in English, 6% in Japanese,
9.4% in Canadian, and 25% in American patients.9,42 Autoan-
ibodies against RNA polymerase 1 and 3 usually coexist in
 prevalence of 20%, and this pattern is highly speciﬁc for
Sc.9,10,12 Anti-RNAP III also has a prognostic role, since it was
elated to diffuse skin involvement, tendon friction rubs, and
idney involvement,9,42,43 but no scleroderma renal crisis was
bserved in our patients. Besides myositis observed in our
atients, studies published in the literature highlights other
igniﬁcant associations between the positivity of anti-RNAP III
ith the occurrence of synovitis and systemic hypertension,
s well as a possible relation to malignancies, predominantly
olid organ cancer.42,43
Unlike systemic lupus erythematosus (SLE), the production
f a speciﬁc autoantibody is unique in patients with SSc, so
he occurrence of more  than one type of antibody in a patient
s rare, except for antibodies against RNA polymerase.9,10,12 5;5 5(3):229–239 237
The coexistence of anti-topo I and ACA in SSc is uncommon
(0.5–5.5%), although some authors have previously consid-
ered it mutually exclusive.44 Although the correlation between
antibodies that deﬁne subtypes of SSc is unusual, the coexis-
tence of ACA or anti-topo I with anti-histone antibodies, ACA
with anti-mitochondrial antibodies, anti-topo I with anticardi-
olipin antibodies, ACA or anti-topo I with Ro (SSA) antibodies,
or anti RNPs with anti Th/To antibodies was described.45 Our
study observed the coexistence of positive anti-topo I and anti-
RNAP III in a patient with diffuse scleroderma.
Based on SHAQ, this study observed higher scores of dis-
ability among patients with positivity of anti-topo I, similar
to those described in other populations of patients with the
diffuse form of SSc.29,46 Comparatively, Morita and colleagues
reported that patients with the diffuse form of SSc had higher
rates of disability on the SHAQ, also higher than those of
patients with RA, SLE and other autoimmune diseases.46 It
was also observed that SSc patients with articular involvement
had higher scores on SHAQ than patients with psoriatic arthri-
tis, while the pain domain was higher in SSc patients than
in RA patients.47 Unpublished data of our patients conﬁrm
the greater disability in the subgroup of patients with arthri-
tis. Recently Iudici and colleagues found that patients with
early form of SSc, despite having only RP, had already expe-
rienced an impairment of quality of life in both physical and
mental domains.48 Accordingly, our 3 patients with the early
form showed a disability index measured by the SHAQ that
was comparable to other groups. The usefulness of SHAQ in
the evaluation of patients with SSc has been demonstrated by
studies that reported that it can predict the evolution and sur-
vival in these patients.29,49 In this work, there was a signiﬁcant
positive linear correlation between SHAQ and disease activ-
ity as measured by the Pearson test. Medsger and colleagues
found that the rates of disability measured by SHAQ showed
strong correlation with skin thickening, cardiac involvement,
digital contractures, tendon friction rubs, and renal involve-
ment in 1000 patients with SSc.26
In conclusion, this study conﬁrms the important role of
speciﬁc autoantibodies in the evaluation of patients with SSc.
It is possible to correlate the antibody proﬁle of this national
population with some distinct clinical manifestations of the
disease.
Conclusions
We  highlight, in agreement with the literature, that the clin-
ical subtype of the disease and some clinical manifestations
in SSc may correlate positively with the presence of speciﬁc
autoantibodies.
The presence of ACA was observed, particularly in the early
forms of the disease, limited scleroderma, and overlap syn-
drome, with absence in the diffuse scleroderma. The anti-topo
I was mainly observed in the diffuse and overlap forms, being
absent in the limited disease.
Patients with positive anti-topo I have higher disease activ-by SHAQ index.
Anti-topo I-positive patients have more  objective RP and
digital pitting scars of ﬁngertips, patients positive for ACA had
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more  telangiectasia and patients with positive anti-RNAP III
antibody had more  muscle atrophy.
The speciﬁc autoantibodies may directly contribute to the
patient’s evolution and prognosis.
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